Condition
QT Interval Prolongation
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (2)
Trial Status
Completed2
Not Yet Recruiting1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07732283Not ApplicableNot Yet Recruiting
4-electrode ECG (DigitalCardio®) vs Standard 10-electrode ECG: Evaluating Ease of Use and Recording Quality
NCT07684768Completed
IMPACT OF CARDIAC AUTONOMIC NEUROPATHY ON QT AND QTC INTERVAL
NCT02898337CompletedPrimary
Methadone-Induced QT Interval Prolongation in a Narcotic Treatment Center
NCT01653990Not ApplicableUnknownPrimary
Moxifloxacin_QT Study in Chinese Healthy Volunteer
Showing all 4 trials